China: Patent granted to Doudna-Charpentier

In June 2017, China’s State Intellectual Property Office awarded a broad CRISPR-Cas9 patent to the Doudna-Charpentier team covering the single-guide RNA format of the CRISPR-Cas9 system and its use in any environment (including plant, animal and human cells). The Chinese patent also includes claims covering the use of CRISPR-Cas9 in producing medicines for treating disease.



Sign up to receive updates from the CRISPR Collective

Related News

U.S. Patent and Trademark Office issued U.S. Patent No. 10,266,850 (‘the ‘850 patent), to The Regents of the University of California, the University of Vienna, and Dr. Emmanuelle Charpentier
European Patent Office (EPO) awarded the Doudna-Charpentier team a broad CRISPR-Cas9 patent (EP Patent No. 3 401 400)
U.S. patent office issued third CRISPR patent to CVC; indicates it will issue a fourth
Read moreArrow-down